Genomic Diversity of Hepatitis B Virus Infection Associated With Fulminant Hepatitis B Development

Authors Information
Article Notes and Dates
To Cite : Mina T, Amini-Bavil-Olyaee S, Tacke F, Maes P, Van Ranst M, et al. Genomic Diversity of Hepatitis B Virus Infection Associated With Fulminant Hepatitis B Development, Hepat Mon. 2015 ;15(6):e29477. doi: 10.5812/hepatmon.29477v2.
Copyright: Copyright © 2015, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
Abstract
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
Acknowledgements
Footnotes
References
  • 1. Rakela J, Lange SM, Ludwig J, Baldus WP. Fulminant hepatitis: Mayo Clinic experience with 34 cases. Mayo Clin Proc. 1985; 60(5): 289-92[PubMed]
  • 2. Polson J, Lee WM, American Association for the Study of Liver D. AASLD position paper: the management of acute liver failure. Hepatology. 2005; 41(5): 1179-97[DOI][PubMed]
  • 3. Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002; 137(12): 947-54[PubMed]
  • 4. Trey C, Lipworth L, Chalmers TC, Davidson CS, Gottlieb LS, Popper H, et al. Fulminant hepatic failure. Presumable contribution to halothane. N Engl J Med. 1968; 279(15): 798-801[DOI][PubMed]
  • 5. Bernuau J, Goudeau A, Poynard T, Dubois F, Lesage G, Yvonnet B, et al. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology. 1986; 6(4): 648-51[PubMed]
  • 6. O'Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet. 1993; 342(8866): 273-5[PubMed]
  • 7. Gimson AE, O'Grady J, Ede RJ, Portmann B, Williams R. Late onset hepatic failure: clinical, serological and histological features. Hepatology. 1986; 6(2): 288-94[PubMed]
  • 8. Liang TJ. Hepatitis B: the virus and disease. Hepatology. 2009; 49(5 Suppl)-21[DOI][PubMed]
  • 9. Panassie L, Borentain P, Nafati C, Bernardin G, Doudier B, Thibault V, et al. Fatal fulminant primary hepatitis B virus infections with G1896A precore viral mutants in southeastern France. Clin Res Hepatol Gastroenterol. 2012; 36(1)-8[DOI][PubMed]
  • 10. O'Grady JG. Acute liver failure. Postgrad Med J. 2005; 81(953): 148-54[DOI][PubMed]
  • 11. Jayakumar S, Chowdhury R, Ye C, Karvellas CJ. Fulminant viral hepatitis. Crit Care Clin. 2013; 29(3): 677-97[DOI][PubMed]
  • 12. Hadem J, Tacke F, Bruns T, Langgartner J, Strnad P, Denk GU, et al. Etiologies and outcomes of acute liver failure in Germany. Clin Gastroenterol Hepatol. 2012; 10(6): 664-9 e2[DOI][PubMed]
  • 13. Oketani M, Ido A, Uto H, Tsubouchi H. Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res. 2012; 42(7): 627-36[DOI][PubMed]
  • 14. Mindikoglu AL, Regev A, Schiff ER. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol. 2006; 4(9): 1076-81[DOI][PubMed]
  • 15. Lee WM. Acute liver failure. N Engl J Med. 1993; 329(25): 1862-72[DOI][PubMed]
  • 16. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013; 144(7): 1426-37[DOI][PubMed]
  • 17. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis. 2002; 2(7): 395-403[PubMed]
  • 18. Echevarria JM, Avellon A. Hepatitis B virus genetic diversity. J Med Virol. 2006; 78 Suppl 1-42[DOI][PubMed]
  • 19. Kay A, Zoulim F. Hepatitis B virus genetic variability and evolution. Virus Res. 2007; 127(2): 164-76[DOI][PubMed]
  • 20. Chotiyaputta W, Lok AS. Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol. 2009; 6(8): 453-62[DOI][PubMed]
  • 21. Pourkarim MR, Amini-Bavil-Olyaee S, Verbeeck J, Lemey P, Zeller M, Rahman M, et al. Molecular evolutionary analysis and mutational pattern of full-length genomes of hepatitis B virus isolated from Belgian patients with different clinical manifestations. J Med Virol. 2010; 82(3): 379-89[DOI][PubMed]
  • 22. Chen L, Zheng CX, Lin MH, Huang ZX, Chen RH, Li QG, et al. Distinct quasispecies characteristics and positive selection within precore/core gene in hepatitis B virus HBV associated acute-on-chronic liver failure. J Gastroenterol Hepatol. 2013; 28(6): 1040-6[DOI][PubMed]
  • 23. Pourkarim MR, Lemey P, Amini-Bavil-Olyaee S, Maes P, Van Ranst M. Novel hepatitis B virus subgenotype A6 in African-Belgian patients. J Clin Virol. 2010; 47(1): 93-6[DOI][PubMed]
  • 24. Pourkarim MR, Amini-Bavil-Olyaee S, Kurbanov F, Van Ranst M, Tacke F. Molecular identification of hepatitis B virus genotypes/subgenotypes: revised classification hurdles and updated resolutions. World J Gastroenterol. 2014; 20(23): 7152-68[DOI][PubMed]
  • 25. Zoulim F, Berthillon P, Guerhier FL, Seigneres B, Germon S, Pichoud C, et al. Animal models for the study of HBV infection and the evaluation of new anti-HBV strategies. J Gastroenterol Hepatol. 2002; 17 Suppl-3[PubMed]
  • 26. Kramvis A, Arakawa K, Yu MC, Nogueira R, Stram DO, Kew MC. Relationship of serological subtype, basic core promoter and precore mutations to genotypes/subgenotypes of hepatitis B virus. J Med Virol. 2008; 80(1): 27-46[DOI][PubMed]
  • 27. Kramvis A, Kew MC. Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy. J Viral Hepat. 2005; 12(5): 456-64[DOI][PubMed]
  • 28. Molecular modelling of hepatitis B virus polymerase and adefovir resistance identifies three clusters of mutations. Hepatology. : 246A
  • 29. Norder H, Courouce AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology. 2004; 47(6): 289-309[DOI][PubMed]
  • 30. Okamoto H, Imai M, Tsuda F, Tanaka T, Miyakawa Y, Mayumi M. Point mutation in the S gene of hepatitis B virus for a d/y or w/r subtypic change in two blood donors carrying a surface antigen of compound subtype adyr or adwr. J Virol. 1987; 61(10): 3030-4[PubMed]
  • 31. Carman WF. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat. 1997; 4 Suppl 1: 11-20[PubMed]
  • 32. Peterson DL, Paul DA, Lam J, Tribby ,I, Achord DT. Antigenic structure of hepatitis B surface antigen: identification of the "d" subtype determinant by chemical modification and use of monoclonal antibodies. J Immunol. 1984; 132(2): 920-7[PubMed]
  • 33. Pourkarim MR, Sharifi Z, Soleimani A, Amini-Bavil-Olyaee S, Elsadek Fakhr A, Sijmons S, et al. Evolutionary analysis of HBV "S" antigen genetic diversity in Iranian blood donors: a nationwide study. J Med Virol. 2014; 86(1): 144-55[DOI][PubMed]
  • 34. Pineda-Pena AC, Faria NR, Mina T, Amini-Bavil-Olyaee S, Alavian SM, Lemey P, et al. Epidemiological history and genomic characterization of non-D1 HBV strains identified in Iran. J Clin Virol. 2015; 63: 38-41[DOI][PubMed]
  • 35. Tamada Y, Yatsuhashi H, Masaki N, Nakamuta M, Mita E, Komatsu T, et al. Hepatitis B virus strains of subgenotype A2 with an identical sequence spreading rapidly from the capital region to all over Japan in patients with acute hepatitis B. Gut. 2012; 61(5): 765-73[DOI][PubMed]
  • 36. Suzuki Y, Kobayashi M, Ikeda K, Suzuki F, Arfase Y, Akuta N, et al. Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. J Med Virol. 2005; 76(1): 33-9[DOI][PubMed]
  • 37. McMahon BJ. The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. Hepatol Int. 2009; 3(2): 334-42[DOI][PubMed]
  • 38. Shi YH. Correlation between hepatitis B virus genotypes and clinical outcomes. Jpn J Infect Dis. 2012; 65(6): 476-82[PubMed]
  • 39. Inoue J, Ueno Y, Kawamura K, Yamamoto T, Mano Y, Miura M, et al. Association between S21 substitution in the core protein of hepatitis B virus and fulminant hepatitis. J Clin Virol. 2012; 55(2): 147-52[DOI][PubMed]
  • 40. Gomes-Gouvea MS, Soares MC, Bensabath G, de Carvalho-Mello IM, Brito EM, Souza OS, et al. Hepatitis B virus and hepatitis delta virus genotypes in outbreaks of fulminant hepatitis (Labrea black fever) in the western Brazilian Amazon region. J Gen Virol. 2009; 90: 2638-43[DOI][PubMed]
  • 41. Casey JL, Niro GA, Engle RE, Vega A, Gomez H, McCarthy M, et al. Hepatitis B virus (HBV)/hepatitis D virus (HDV) coinfection in outbreaks of acute hepatitis in the Peruvian Amazon basin: the roles of HDV genotype III and HBV genotype F. J Infect Dis. 1996; 174(5): 920-6[PubMed]
  • 42. Wai CT, Fontana RJ, Polson J, Hussain M, Shakil AO, Han SH, et al. Clinical outcome and virological characteristics of hepatitis B-related acute liver failure in the United States. J Viral Hepat. 2005; 12(2): 192-8[DOI][PubMed]
  • 43. Victoria Fda S, Oliveira CM, Victoria MB, Victoria CB, Ferreira LC. Characterization of HBeAg-negative chronic hepatitis B in western Brazilian Amazonia. Braz J Infect Dis. 2008; 12(1): 27-37[PubMed]
  • 44. Baig S, Siddiqui AA, Ahmed W, Qureshi H, Arif A. The association of complex liver disorders with HBV genotypes prevalent in Pakistan. Virol J. 2007; 4: 128[DOI][PubMed]
  • 45. Erhardt A, Blondin D, Hauck K, Sagir A, Kohnle T, Heintges T, et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut. 2005; 54(7): 1009-13[DOI][PubMed]
  • 46. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005; 365(9454): 123-9[DOI][PubMed]
  • 47. Pourkarim MR, Lemey P, Amini-Bavil-Olyaee S, Houspie L, Verbeeck J, Rahman M, et al. Molecular characterization of hepatitis B virus strains circulating in Belgian patients co-infected with HIV and HBV: overt and occult infection. J Med Virol. 2011; 83(11): 1876-84[DOI][PubMed]
  • 48. Fernholz D, Galle PR, Stemler M, Brunetto M, Bonino F, Will H. Infectious hepatitis B virus variant defective in pre-S2 protein expression in a chronic carrier. Virology. 1993; 194(1): 137-48[DOI][PubMed]
  • 49. Bartholomeusz A, Locarnini S. Hepatitis B virus mutants and fulminant hepatitis B: fitness plus phenotype. Hepatology. 2001; 34(2): 432-5[DOI][PubMed]
  • 50. Kitab B, Essaid El Feydi A, Afifi R, Trepo C, Benazzouz M, Essamri W, et al. Variability in the precore and core promoter regions of HBV strains in Morocco: characterization and impact on liver disease progression. PLoS One. 2012; 7(8)[DOI][PubMed]
  • 51. Wright TL, Mamish D, Combs C, Kim M, Donegan E, Ferrell L, et al. Hepatitis B virus and apparent fulminant non-A, non-B hepatitis. Lancet. 1992; 339(8799): 952-5[PubMed]
  • 52. Sterneck M, Kalinina T, Gunther S, Fischer L, Santantonio T, Greten H, et al. Functional analysis of HBV genomes from patients with fulminant hepatitis. Hepatology. 1998; 28(5): 1390-7[DOI][PubMed]
  • 53. Kalinina T, Riu A, Fischer L, Will H, Sterneck M. A dominant hepatitis B virus population defective in virus secretion because of several S-gene mutations from a patient with fulminant hepatitis. Hepatology. 2001; 34(2): 385-94[DOI][PubMed]
  • 54. Bock CT, Tillmann HL, Maschek HJ, Manns MP, Trautwein C. A preS mutation isolated from a patient with chronic hepatitis B infection leads to virus retention and misassembly. Gastroenterology. 1997; 113(6): 1976-82[PubMed]
  • 55. Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology. 1998; 27(1): 213-22[DOI][PubMed]
  • 56. Bagaglio S, Albarello L, Biswas P, Uberti-Foppa C, Fortis C, Morsica G. Virological pattern of hepatitis B infection in an HIV-positive man with fatal fulminant hepatitis B: a case report. J Med Case Rep. 2009; 3: 110[DOI][PubMed]
  • 57. Pollicino T, Zanetti AR, Cacciola I, Petit MA, Smedile A, Campo S, et al. Pre-S2 defective hepatitis B virus infection in patients with fulminant hepatitis. Hepatology. 1997; 26(2): 495-9[DOI][PubMed]
  • 58. Pollicino T, Cacciola I, Saffioti F, Raimondo G. Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications. J Hepatol. 2014; 61(2): 408-17[DOI][PubMed]
  • 59. Sato S, Suzuki K, Akahane Y, Akamatsu K, Akiyama K, Yunomura K, et al. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med. 1995; 122(4): 241-8[PubMed]
  • 60. Baumert TF, Rogers SA, Hasegawa K, Liang TJ. Two core promotor mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. J Clin Invest. 1996; 98(10): 2268-76[DOI][PubMed]
  • 61. Parekh S, Zoulim F, Ahn SH, Tsai A, Li J, Kawai S, et al. Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. J Virol. 2003; 77(12): 6601-12[PubMed]
  • 62. Amini-Bavil-Olyaee S, Vucur M, Luedde T, Trautwein C, Tacke F. Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains. J Virol. 2010; 84(2): 1026-33[DOI][PubMed]
  • 63. Zheng Y, Li J, Ou JH. Regulation of hepatitis B virus core promoter by transcription factors HNF1 and HNF4 and the viral X protein. J Virol. 2004; 78(13): 6908-14[DOI][PubMed]
  • 64. Sendi H, Mehrab-Mohseni M, Zali MR, Norder H, Magnius LO. T1764G1766 core promoter double mutants are restricted to Hepatitis B virus strains with an A1757 and are common in genotype D. J Gen Virol. 2005; 86: 2451-8[DOI][PubMed]
  • 65. Gerolami R, Henry M, Borentain P, Colson P, Botta D, Tamalet C. Fulminant hepatitis B associated with a specific insertion in the basal core promoter region of hepatitis B virus DNA after immunosuppressive treatment. Clin Infect Dis. 2005; 40(4)-7[DOI][PubMed]
  • 66. Imamura T, Yokosuka O, Kurihara T, Kanda T, Fukai K, Imazeki F, et al. Distribution of hepatitis B viral genotypes and mutations in the core promoter and precore regions in acute forms of liver disease in patients from Chiba, Japan. Gut. 2003; 52(11): 1630-7[PubMed]
  • 67. Hou J, Lin Y, Waters J, Wang Z, Min J, Liao H, et al. Detection and significance of a G1862T variant of hepatitis B virus in Chinese patients with fulminant hepatitis. J Gen Virol. 2002; 83: 2291-8[PubMed]
  • 68. Kusakabe A, Tanaka Y, Mochida S, Nakayama N, Inoue K, Sata M, et al. Case-control study for the identification of virological factors associated with fulminant hepatitis B. Hepatol Res. 2009; 39(7): 648-56[DOI][PubMed]
  • 69. Sugiyama M, Tanaka Y, Kurbanov F, Nakayama N, Mochida S, Mizokami M. Influences on hepatitis B virus replication by a naturally occurring mutation in the core gene. Virology. 2007; 365(2): 285-91[DOI][PubMed]
  • 70. Torresi J, Earnest-Silveira L, Deliyannis G, Edgtton K, Zhuang H, Locarnini SA, et al. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology. 2002; 293(2): 305-13
  • 71. de Man RA, Bartholomeusz AI, Niesters HG, Zondervan PE, Locarnini SA. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. J Hepatol. 1998; 29(4): 669-75[PubMed]
  • 72. Peters MG, Singer G, Howard T, Jacobsmeyer S, Xiong X, Gibbs CS, et al. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. Transplantation. 1999; 68(12): 1912-4[PubMed]
  • 73. Kaneko M, Uchida T, Moriyama M, Arakawa Y, Shikata T, Gotoh K, et al. Probable implication of mutations of the X open reading frame in the onset of fulminant hepatitis B. J Med Virol. 1995; 47(3): 204-8[PubMed]
  • 74. Jalan R, Gines P, Olson JC, Mookerjee RP, Moreau R, Garcia-Tsao G, et al. Acute-on chronic liver failure. J Hepatol. 2012; 57(6): 1336-48[DOI][PubMed]
  • 75. Laurenti R, Giovannangeli F, Gubinelli E, Viviano MT, Errico A, Leoni L, et al. Long-term safety of anti-TNF adalimumab in HBc antibody-positive psoriatic arthritis patients: a retrospective case series of 8 patients. Clin Dev Immunol. 2013; 2013: 410521[DOI][PubMed]
  • 76. Cantini F, Boccia S, Goletti D, Iannone F, Leoncini E, Panic N, et al. HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-alpha) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis. Int J Rheumatol. 2014; 2014: 926836[DOI][PubMed]
  • 77. Domm S, Cinatl J, Mrowietz U. The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol. 2008; 159(6): 1217-28[DOI][PubMed]
  • 78. European Association For The Study Of The L. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012; 57(1): 167-85[DOI][PubMed]
  • 79. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989; 97(2): 439-45[PubMed]
  • 80. Wiegand J, Wedemeyer H, Franke A, Rossler S, Zeuzem S, Teuber G, et al. Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double-blinded multicentre trial. J Viral Hepat. 2014; 21(10): 744-50[DOI][PubMed]
  • 81. Amini-Bavil-Olyaee S, Trautwein C, Tacke F. Relevance of hepatitis B virus genome variability in organ transplantation. Hepat Mon. 2007; 7(1): 35-41
  • 82. Yu JW, Sun LJ, Yan BZ, Kang P, Zhao YH. Lamivudine treatment is associated with improved survival in fulminant hepatitis B. Liver Int. 2011; 31(4): 499-506[DOI][PubMed]
  • 83. Tillmann HL, Hadem J, Leifeld L, Zachou K, Canbay A, Eisenbach C, et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat. 2006; 13(4): 256-63[DOI][PubMed]
  • 84. Tillmann HL, Patel K. Therapy of acute and fulminant hepatitis B. Intervirology. 2014; 57(3-4): 181-8[DOI][PubMed]
  • 85. Wu TJ, Chen TC, Wang F, Chan KM, Soong RS, Chou HS, et al. Large fragment pre-S deletion and high viral load independently predict hepatitis B relapse after liver transplantation. PLoS One. 2012; 7(2)[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

Hepatitis Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check